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ABSTRACT
A SOLIDPHASEENZYME-LINKEDIMMUNOSORBENTASSAYFORTHEANTIGENIC
DETECTIONOFLEGIONELLA PNEUMOPHILA (SEROGROUP I):
A COMPLIMENT FOR THE SPACE STATION DIAGNOSTIC CAPABILITY
Kelly E. Hejtmancik, Ph.D.
Instructor
Division of Mathematics and Science
Galveston College
Galveston, Texas 77550
It is necessary that an adequate microbiology capability be provided
as part of the Health Maintenance Facility (HMF) to support expected
microbial disease events and environmental monitoring during long periods
of space flight. The applications of morphological and biochemical studies
to confirm the presence of certain bacterial and fungal disease agents are
currently available and under consideration. This confirmation would be
facilitated through employment of serological methods to aid in the
identification of bacterial, fungal, and viral agents.well. A number of
serological approaches are currently being considered, including the use
of Enzyme-Linked Immunosorbent Assay (ELISA} technology, which could be
utilized during microgravity conditions.
A solid phase, membrane supported ELISA for the detection of
Leqionella pneumophila (Serogroup I), an expected disease agent, was
developed to show a potential model system that would meet the HMF
requirements and specifications for the future space station. These
studies demonstrate the capability of membrane supported ELISA systems for
identification of expected microbial disease agents as part of the HMF.
NASA Colleague: Duane L. Pierson, Ph.D. SD4 X3-7166
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INTRODUCTION
The health and well being of individuals aboard a space station and
possibly during future long space missions is of priority and must be
assured. Certain expected clinical syndromes and diseases have been
identified through an infectious disease conference conducted at the
Johnson Space Center during October, 1985. Leqionella pneumophila was
identified as a possible problem due to its tendency to grow in filtration
and water systems. Since 1976, 23 Leqionella species comprising 37
serotypes have been identified. L. pneumophila, the most prevalent
Leqionella species in the United States, currently contains 12 serogroups,
all which have been involved in pneumonia in humans (8). Previous
spaceflight studies indicate a high probability of cross-contamination
among crew members and microbial build up of space modules during long
confinements, such as minimal (90 day) missions which are planned for the
space station (7). Continual habitation, crowded conditions, possible
immunosuppression, and other factors may create critical situations aboard
the space craft. If a microbial disease is suspected, the major effort
would be directed toward obtaining some indication of the specific kind of
microorganism causing the problem. The exact nature of the etiological
agent would determine the severity of the disease, treatment, prophylaxis,
and subsequent health measures for the space station environment.
The diagnosis of a microbial disease currently rests upon one of a
combination of clinical signs and symptoms, morphological and biochemical
identification of isolates, and/or serological procedures. Special
procedures such as cell culture may also be required. One problem with
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limiting the scope of diagnosis to clinical signs and symptomsis that a
particular microbe can sometimes produce infection having very different
clinical characteristics and occurring in widely different areas of the
body. For example, antibiotic-resistant Staphylococcus aureus may produce
skin and subcutaneous tissue lesions as well as pneumonia, osteomyelitis,
bacteremia, and acute membranous enterocolitis depending upon the means by
which the organism gained entrance to the body, host resistance, antibiotic
therapy, and other factors.
While the principle of one microorganism causing one clinical disease
is often valid, there are many situations where this is not true. Indeed,
pneumonias that are hardly separable clinically may be produced by several
different kinds of bacteria and viruses. Correct diagnosis and treatment
therefore heavily depend upon the abilities of the clinical laboratory.
Over the past few years, many new immunological methods have been
developed which now provide the clinical laboratory with a large array of
potentially valuable diagnostic tools. Antibodies and antigens labelled
with radioisotopes or fluorescent dyes, or affixed to particulate
materials, have been used extensively for immunodiagnosis over the past
three decades. These methods do have disadvantages. Immunofluorescence,
for example, usually depends upon a subjective assessment of end result,
and the technique is frequently laborious. Radioimmunoassay requires
expensive equipment and carries the risk of radioactive exposure and
contamination. Moreover, the current methods for either technology are not
applicable to microgravity. The concepts that antigen and antibody can be
attached to a solid phase support yet retain immunological activity, and
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that either can be coupled to an enzyme and the complex retain both
immunological and enzymatic activity, led to the development of
Enzyme-Linked Immunosorbent Assays (ELISAs). Antibodies and antigens have
been shown to readily attach to plastic surfaces (such as polyvinyl or
polystyrene) either by passive absorption or chemical conjugation, and
still retain immunological activity. Antibodies and antigens have been
linked to a variety of enzymes including glucose oxidase, peroxidase, and
alkaline phosphatase. Table i indicates the positive factors for use of
ELISA systems in diagnostic microbiology.
Table 1: Positive Factors for HMF
Consideration of ELISA Systems.
_' Low Cost
,' Reagent stability
_' g_ty
_' S_sitivity
-' Sl_:_ificity
.t Reproducibility
4 Ease of procedure
,t Can be performed in poorly equipped
laboratories
J' No power requirements
It appears that the space station diagnostic capability will most
likely require immunological testing applicable to the identification of
microorganisms, particularly those that cannot be cultured or identified by
standard laboratory techniques. In recent years, there has been increasing
emphasis on accurate, reliable, .and quick immunological procedures for the
identification of many microorganisms and/or the immunological responses of
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the host toward infection. Most current commercially available procedures
have been developed for use in clinical laboratories and not designed for
microgravity conditions which would be present in the space station
environment (55. It appears and is reasonable that a numberof some
existing procedures, particularly solid phase immunoassays, could be
modified in regard to uniformity and standardization for use aboard the
space station. This project was designed to illustrate the concept of a
solid phase, membranesupported ELISA for detection of L. pneumophila
(Serogroup 15 to demonstrate the capability of ELISA systems for
identification of expected microbial disease agents aboard the space
station.
MATERIALS
Equipment' A 96 well Bio-Dot filtration apparatus (#i _" _=="• ID-_D) was
obtained from Bio-Rad Laboratories, Richmond, Ca. 94801.
Buffers: A 20 mM Tris buffered saline (TBS), pH 7.5, was prepared by
adding 4.84 g Tris (Bio-Rad) to 58.4B g NaCI, brought to a 2 liter volume
with deionized water• The buffer was adjust to pH 7.5 with I M HCI.
Blocking Solution: Bovine serum albumin (BSA, #A-70305 was purchased
from Sigma• A 3% BSA-TBS was prepared by adding 3 g of BSA to 100 ml of
TBS.
Wash Solution: A wash solution containing 0.05% Tween-20 was prepared
by adding 0.5 ml of Tween-20 (Bio-Rad) to 1 liter of TBS.
Antibodies: Antisera prepared in rabbits against L. pneumophila
(strain Philadelphia .I and OLDA5 were obtained from Dr. Hazel Wilkinson,
the Department of Health and Human Services, Center for Disease Control,
13-6
Atlanta, Ga. 30333. These antisera were pooled for coverage of all
serogroup I subtypes (9). Horseradish perioxidase conjugated (HPR) goat
anti-rabbit serum (#170-6500) was obtained from Bio-Rad Laboratories.
Nitrocellulose Membranes: Nitrocellulose membranes(#162-0117) with a
pore size of 0.45 microns was purchased from Bio-Rad Laboratories.
Legionella Antigen: L. pneumophila antigen was prepared from an ATCC
3152 (serogroup I) lyophilized culture vial (3). The lyophilized culture
vial was broken and the lyophilized material was dissolved into 4 ml of
Trypticase Soy Broth. Four 15 x 100 mm plates containing 25 ml of buffered
charcoal yeast extract (BCYE) agar each of which was inoculated with i ml
of the dissolved material. The plates were enclosed in a plastic container
to prevent the agar from drying out and were incubated at 35 degrees
centigrade for 48 hr. The cells were suspended from each agar surface in 3
ml of sterile 0.01M phosphate buffered saline, pH 7.2, with a pasteur
pipette into a 25 ml sterile conical tube. The conical tube containing the
cell suspension was boiled for I hr to kill the cells. The killed cell
suspension was centrifuged at 1600 x g for 30 min, the supernatant
discarded, and the cells resuspended in 2 ml of 0.01 M phosphate buTTer, oH
7.2, for each 0.1 ml of packed cells. One drop of a 1:1000 methiolate
solution was added for each 2 ml of preparation. The stock solution was
stored at 4 degrees centigrade for 10 days to allow for the release of
soluble antigen from the cells. The suspension was centrifuged at 1600 x g
and the supernatant used for assay development. The antigen preparation
was subjected to the Lowry protein detection method indicating the antigen
preparation concentration was approximately 0.025 mg/ml. Subsequent
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calculations were determined from this estimate.
Stock ChromogenicSubstrate Stain Solution: Twosubstrates were
utilized for comparison. O-phenylenediamine (OPD,Abbott Laboratories) was
prepared by dissolving 12.8 mg into 5 ml of citrate phosphate buffer, pH
7.2, containing 0.02% hydrogen peroxide. 4-chloro-l-napthol (4CIN,
Bio-Rad) was prepared by dissolving 60 mgof 4CIN into 20 ml of ice cold
methanol. Immediately prior to use, 0.06 ml of ice cold 30%hydrogen
peroxide was added to 100 ml of room temperature TBS. The two solutions
were mixed just prior to use.
Preparations Obtained for Specificity Studies: All antigen
preparations tested were obtained from Difco Laboratories. These
preparations included Salmonella 0 Poly A-I and Vi (#2364-47-2) which
contains antigens from Group A, B, CI, C2, D2, El, E2, E4, F, G, H, I, and
Vi; Shiqella Group A (#2100-50-I), AI (#2101-50-3), B (#2102-50-2), C
(#2103-50-0), CI (#2104-50-0), C2 (#2105-50-9), and D (#2106-50-8);
Pseudomonas aeruqinosa antigen set (#3082-32-7); Streptococcus antigen set
containing Groups A, B, C, D, E, F, and G (#2368-32-4).
Immunofluorescent Assay Kit: A MonAbrite Leqionella Polyscreen kit
was obtained from Serono Diagnostics, Inc., 100 Longwater Circle, Norwell,
MA 02061 and used for comparison with results obtained by the ELISA. This
kit recognizes 21 species and 33 serogroups of Leqionella including
Serogroup I.
METHODS
The ELISA system utilized the Bio-Dot apparatus with mounted
nitrocellulose paper. The procedure for assembly of the apparatus and
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preparation of the nitrocellulose paper was provided by Bio-Rad
Laboratories (I). Figure I illustrates the basic componentsof the
system. Nitrocellulose paper was first soaked in TBSto ensure uniform
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Enzyme Subatrate
(OPD or 401N)
Horseradish Peroxidase-Labelled
Goat Anti-Rabbit
Rabbit Antl-[. oneumoohila
I,. _ AnUgen
Nltrocelluloee Paper
Figure 1: Major components of the ELISA
for L.._J_al_la.
protein bindings and low background absorption. The cleaned and dried
Bio-Dot apparatus was assembled, and the nitrocellulose paper sheet wetted
prior to being placed in the apparatus. The apparatus was appropriately
tightened to insure that cross well contamination would not occur.
The flow valve was adjusted to allow the vacuum chamber to be exposed
to the atmosphere and the appropriate wells to receive antigen preparations
were inoculated with a 0.05 ml volume. The entire sample was allowed to
filter through the membrane by gravity flow (approximately 30 min). Each
well was filled with the same volume of sample solution to insure
homogeneous filtration of all sample wells.
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After the antigen samples completely drained from the apparatus, 0.2
ml of a 3% BSA/TBS blocking solution was applied to each well. Gravity
filtration was allowed to occur until the blocking solution completely
drained from each well (approximately 30 min).
The flow valve was adjusted to vacuum and 0.4 ml of wash solution (TBS
with 0.05% tween) was added to each well. The wash solution was allowed to
completely drain from all wells. This process was repeated. Following the
wash step, the flow valve was opened to the atmosphere and 0.1 ml of the
rabbit anti-Leqionella antibody solution was added to each of the wells.
The solution was allowed to completely drain from the wells, and another
wash step performed.
With the vacuum off and the flow valve to the atmosphere, 0. I ml of
horseradish peroxidase labelled goat anti-rabbit solution was added to each
well. The solution was allowed to completely drain from the wells.
Following the second antibody step, the vacuum was turned on and a
wash step performed. Immediately, 0.2 ml of a Color development solution,
either OPD or 4CIN was applied to each well. A positive ELISA reaction was
shown as color development depending upon the substrate utilized. The
reactions were stopped by the addition of 0.3 ml of distilled deionized
water to each well.
The MonAbrite Leqionella Polyscreen (Serono Diagnostics, Inc)
Immunofluroescent Assay Kit was accomplished by the procedure which
accompanied the package. Briefly, test specimens and controls were applied
as 0.05 ml aliquots to slides and heat fixed. Rabbit anti-Leqionella was
applied to each specimen with the exception of the control wells. After a
13-10
30 min incubation period, a wash procedure was performed. The slides were
air dried and FITC-labelled goat anti-rabbit serum was applied to each
specimen. Slides were washed, air dried, and examined for
immunofluorescence utilizing a Nikon Episcopic-Fluorescence microscope with
a B-IA filter cube.
RESULTS
Assay sensitivity: Dose response curves utilizing decreasing
concentrations of L_ pneumophila (Serogroup I) antigen applied to the
nitrocellulose membrane and titrated with increasing dilutions of L.
pneumophila (Serogroup I) antibody are shown in Figure 2. The reaction
intensity was measured by eye from 0 to 4+, 4+ graded as the most intense
of the color outcome. O-phenylenediamine was the substrate used in these
experiments. As the antibody was diluted, the sensitivity of the ELISA was
shown to decrease. Dilutions of antibody tested between 1:10 and 1:100
allowed the detection of L. pneumophila antigen to 0.0626 ng (62.6 pg);
o
whereas, antibody dilutions of 1:500, 1:1000, 1:5000, and 1:10000 reduced
the sensitivity of the ELISA to 0.3442, 0.626, 6.26, and 34.43 ng,
respectively. Antibody dilutions including and exceeding 1:50000 did not
allow for detection of L. pneumophila antigen. The optimal dilution of
antibody for used in the ELISA was determined to be 1:100.
Assay specificity: Available antigen preparations from other bacterial
groups were applied to the nitrocellulose membrane to test for cross
reactivity with the anti-L_, pneumophila serum. As indicated in Table 2, no
cross-reactivity was detectable between the various groups or types of
Salmonella, Shiqella, Pseudomonas, or Streptococcus when these
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Reaction Intensity (0 - 4+)
4 _\
3
2
I "'_ ,
0
(52.6 34,43 (5,26 3.443 ,62B ,3442 ,0826 .0344
L, pneumophila Antigen Preparation (ng)
1'.10 Jr- 1'.50 + 1'.100 --8- 1'.500
1'.1000 --e-- 1:6000 --,a,- 1:10000 + 1'.,50000
Figure 2: Titration of L. _ (Serogroup 1) antigen and antibody
preparations by ELISA methods. (Note: intervals are not equal unlts)
preparations were applied to the nitrocellulose membrane and tested by the
o
ELISA. Each o{ the preparations were tested as 10x dilutions {tom the
stock to a {inal dilution o{ 1:1000. Five urine, blood plasma, and two
sputum samples were applied to the nitrocellulose membrane and were
negative when tested by the ELISA. Dose response curves were not a{{ected
by either biological {luidwhen L. pneumophila was seeded into these
specimens and applied to the nitrocellulose membrane.
Comparison of sensitivity between ELISA and IFA methods: The
pneumophila antigen preparation was titrated by the MonAbrite Leqionella
Polyscreen kit (Serono Diagnostics, Inc.) and compared to that achieved by
ELISA. The IFA results were based upon the brightness o÷ ÷ield (0 to 4+)
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]able 2: Antigens and Biological Fluids
Testing Negative in the ELISA.
Salmonella
Groups A,B,C1,C2,D2,E1,E2,E4,F,G,H,I,Vi
Shiaella
Groups A,A1,B,C,C1,C2,D
Types 1-17
Groups A,B,C,D,E,F,G
Urine
Blood plasma
, Sputum
with relationship to the diluted antigen preparation. As indicated in
Figure 3, ELISA results are similar to that indicated in Figure 2 for the
standard dose response curve with minimum antigen detection between 0.0626
and 0.0344 ng. IFA results indicate a minimum detection limit of 0.b26 ng
of antigen, an approximate 10 fold reduction in sensitivity when compared
with the results of the ELISA. A dilution curve of the polyvalent antigen
control in the IFA kit was titrated by dilution using both ELISA and IFA
techniques. In these determinations the ELISA was capable of detecting the
control specimen to a 1:50 dilution; whereas, the IFA was readable to a
1:10 dilution. Since the Serono IFA kit is polyvalent and not specific
toward Serogroup I, strict interpretation of the comparsion of the
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Reaution Intensity (0 - 4,-)
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62,6 34.4a 6.2e a,443 .626 .3442 ,o626 ,0344 .oo626
L. pneumophila Antigen Preparation (ng)
ELISA ---4-- IFA
Figure 3: Measurement of L,. _ antigen (Serogroup 1)
preparation by ELISA and IFA methods.
companion polyvalent antigen control between the two methods is not valid.
However, in these determinations the ELISA was capable capable of detecting
the control specimen to a 1:50 dilution; whereas, the IFA was readable to a
1:10 dilution.
Comparison o{ OPD and 4CIN as enzyme substrates: OPD (O-phenylenediamine)
and 4CIN (4-chloro-l-napthol) were compared in the ELISA for their
performance to detecting _ pneumophila antigen. As shown in Figure 4, the
OPD was capable of detecting lesser amounts o{ antigen than 4CIN. Only
34.43 ng was detectable with 4CIN.
DISCUSSION
It appears logical that the methods selected {or the diagnostic
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Figure 4. Comparison of OPD and 4C1N as Substrates
in the ELI,_.
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34.48 6.26 8.448
systems Health Maintenance Facility (HMF) as well as microbiological
environmental monitoring of space stations and vehicles will need to
support identification of microorganisms that pose a health threat to the
astronauts. A closed environmental system makes its necessary to monitor
surfaces, water, air, waste systems, and possibly food for contamination
with microorganisms. The growth of microorganisms in a closed recycled
environment increases the potential for cross-contamination of crew members
particularly when missions of 3 months and possible missions to Mars (I-3
years) are being considered. Depending upon the humidity and organic
debris build-up in this environment, microorganisms may grow uninhibited.
It is evident that the HMF and environmental monitoring systems must be in
13-15
place for microbial detection since quick return trips will be
impossible. Thus, detection of a microbial problem could result in
methods applied to eliminate that situation before more serious problems
develop. Illnesses caused by microorganisms vary significantly in regards
to symptoms, severity, prophylaxis, and treatment. As experienced during
Apollo 13, a urinary tract infection with Pseudomonas aeruqinosa could have
resulted in a serious situation if the crew member had not been able to
receive immediate health care (4). The potential for cross-contamination
of crew members has been documented by chamber tests and experiences aboard
the Skylab missions (2). These situations provide evidence that adequate
microbiological diagnostic systems be in place aboard space vehicles or
stations prior to their habitation for long time periods. There is
currently considerable debate of on the effects of microgravity, radiation,
temperature, and pressure on man, particularly immunosuppressive effects.
If immunosuppression is indeed a reality during long space missions, the
HMF must have the capability to not only provide identification of a
microbial problem, but also medication against the invading
microorganisms. During the past decade, numerous immunoassays have gained
wide acceptance as the method of choice in the diagnosis of numerous
disease states (6). The ideal considerations of a diagnostic test
particularly for the NASA space program include speed, sensitivity,
specificity, accuracy, safety, inexpensive reagents, potential for
automation, long reagent shelf life, and broad applicability. Moreover,
they must function in microgravity and not contain biologicals which
would themselves threaten the health of the crew members. Although
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many techniques have been recently developed for the immunological
detection of antigens and/or antibodies, enzymeimmunoassayssuch as the
ELISAs are amongthe most popular both in research and clinical
laboratories for the diagnosis of bacteria, protozoans, and viruses (5).
In general, ELISAs are user-friendly, reliable, highly sensitive and
specific, and require little time to run. Additional considerations
include that no power source or instruments are required for the
performance of the tests, little equipment is needed, reagents are stable,
and results can be read by eye as intensive color changes.
The majority of commercially available ELISA systems are designed to
detect antibody levels in blood plasma or other biological fluids such as
urine and few have been developed for the detection of microbial antigens.
At the present time, commercially available ELISA systems were not designed
to be utilized in microgravity, and thus, little concern was given to
designing these tests for those conditions. Only one ELISA, the Test Pack
by Abbott Laboratories, released in June, 1986 for purchase, appears
promising for space station use. This test detects the presence of
Streptococcus pyoqenes (Stoup A, beta-hemolytic streptococci) directly from
throat swabs. The test performed well when tested aboard the KC 135 which
simulates microgravity during parabolic curves.
Results from experiments conducted in this project and the existence
of a commercially available kit paralleling these findings, provide a
current technology to be considered for the HMF and environmental
monitoring systems for space vehicles and stations. A major advantage to
consider with the solid phase filter membrane systems is that the fluids
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involved in the system can be retained resulting in little chance of
spillage in the spacecraft environment. This project also presents an
ELISA developed against Leqionella pneumophila (Serogroup I), the causative
agent of Legionaires' disease. Because of its habitat, growth in filter
and condensation units, this bacteria poses a possible health threat
particularly in a closed recycled environment as that indicated aboard the
space station and future space vehicles. The ELISA developed in this
project could be utilized for monitoring and detecting its presence and
levels in filters and condensates aboard these space crafts as well as to
test a crew member for its presence in a respiratory disease syndrome.
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